How much funding has Kyverna Therapeutics raised?

Kyverna Therapeutics has raised $110.0M in total funding, most recently a Series B round.

Who are Kyverna Therapeutics's investors?

Kyverna Therapeutics's investors include Gilead Sciences, Vida Ventures.

When was Kyverna Therapeutics founded?

Kyverna Therapeutics was founded in 2018.

Where is Kyverna Therapeutics headquartered?

Kyverna Therapeutics is headquartered in Emeryville, California, United States.

What industry is Kyverna Therapeutics in?

Kyverna Therapeutics operates in Healthcare, Life Sciences.

How many employees does Kyverna Therapeutics have?

Kyverna Therapeutics has 51-200 employees.

Kyverna Therapeutics

IPO

Kyverna is Developing Cell Therapies for Autoimmune Diseases

Public · Emeryville, United States · Founded 2018 · $110.0M raised

Healthcare

Life Sciences

Headquarters: Emeryville, California
Employees: 51–200
Founded: 2018
Business Model: B2B
Website: kyvernatx.com

Total Funding: $110.0M
Last Round: $85.0M Series BAug 2023
Rounds: 2
Type: Public

About

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing CAR T-cell therapies designed to achieve treatment-free remission in autoimmune diseases. Its lead candidate, mivocabtagene autoleucel (KYV-101), is in Phase 2 trials across lupus nephritis, multiple sclerosis, myasthenia gravis, and stiff-person syndrome. Kyverna went public on Nasdaq in February 2024.

Summary

Kyverna Therapeutics is a Healthcare company based in Emeryville, United States, founded in 2018. It has raised $110.0M in total across 2 rounds, most recently a $85.0M Series B round in Aug 2023. Investors include Gilead Sciences and Vida Ventures.